Cancer Gene Therapy Market to Reach $16 Billion by 2033 as Immunotherapy Reshapes Oncology

The global cancer gene therapy market is expected to reach $16 billion by 2033, up from $3.6 billion in 2023, growing at a compound annual growth rate of 16.1% during the forecast period from 2024 to 2033. North America emerged as the dominant region, securing over 36.5% of the market share with a valuation of $1.3 billion for the year.

The broader global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035, as immunotherapy continues to reshape the standard of care across solid tumors and hematologic cancers. Cancer drug revenues alone are expected to reach $335.2 billion by 2033, driven by the rapid clinical adoption of targeted therapies, checkpoint inhibitors, and next-generation cell therapies.

The immuno-oncology segment is forecast to expand from $65.22 billion in 2025 to $170.19 billion by 2032 at a compound annual growth rate of 14.9%, driven by rising cancer prevalence and a wave of combination therapy approvals. Immunotherapy drug development remains the fastest-growing area of oncology R&D, with checkpoint inhibitors, cancer vaccines, and cell therapies collectively attracting record levels of clinical investment.

In 2023, gene induced immunotherapy emerged as the dominant therapy type within the cancer gene therapy market, accounting for 38.22% of the overall market share. Within the indication segment, gene induced immunotherapy also maintained a leading position in 2023, representing 31.51% of the total market share. Biopharmaceutical companies constituted the primary end-user segment in 2023, contributing 48.62% to the overall cancer gene therapy market revenue.

Cancer gene therapy represents a significant advancement in modern oncology, focusing on modifying or replacing defective genes responsible for tumor development and progression. This innovative therapeutic approach is designed to target cancer at the molecular level, offering a more precise and personalized alternative to conventional treatments such as chemotherapy and radiation therapy. The basic foundation of cancer gene therapy involves the introduction, removal, or alteration of genetic material within a patient's cells. Functional genes are delivered into cancer cells using safe viral or non-viral vectors, enabling the correction of abnormal genetic activity.

Clinical trials have demonstrated promising outcomes across multiple cancer types, including leukemia, lymphoma, and solid tumors. Advancements in gene-editing technologies, such as CRISPR-based platforms, have further enhanced precision and therapeutic potential. The growth of cancer gene therapy research can be attributed to increasing cancer incidence worldwide and rising investment in advanced biotechnologies.

The gene therapy bioassays market has seen remarkable growth recently, increasing from $1.21 billion in 2025 to an anticipated $1.41 billion in 2026, with a robust CAGR of 16.5%. This surge is largely due to the expansion of gene therapy research programs, growth in viral vector manufacturing capabilities, rising clinical trial activities, adoption of standardized bioassay protocols, and heightened regulatory scrutiny on gene therapy products. Looking ahead, the market is projected to expand further, reaching $2.62 billion by 2030 at a CAGR of 16.7%.

A key driver for the gene therapy bioassays market is the increasing number of gene therapy clinical trials underway globally. These trials evaluate gene-based treatments for safety, efficacy, and biological performance in humans. The surge in clinical studies results from intensified R&D efforts and rising investments by biopharmaceutical firms aiming to develop innovative genetic therapies targeting unmet medical needs. In January 2026, the UK Bioindustry Association reported 193 ongoing advanced therapy clinical trials within the country, over 80% focused specifically on gene therapies.

In 2025, North America led the gene therapy bioassays market in terms of size, supported by advanced infrastructure, strong biopharmaceutical presence, and regulatory frameworks conducive to innovation. Meanwhile, the Asia-Pacific region is forecast to be the fastest-growing market over the coming years, driven by increasing investments in biotechnology, expanding clinical trial networks, and growing focus on genetic medicine.

North America's market dominance was supported by the high prevalence of cancer, which has sustained strong demand for advanced therapeutic solutions. The presence of a well-developed healthcare infrastructure and continuous investment in biotechnology and medical research further strengthened regional growth. The region benefits from advanced technological capabilities and the concentration of major biotechnology firms and research institutions engaged in genetic and oncology innovation. Favorable government initiatives, along with substantial public and private funding, have accelerated research and commercialization activities. A structured regulatory environment has enabled relatively faster approvals of gene-based therapies, facilitating timely market entry.